RA Capital Management ENTA Position
Exited3-Fund ConvergenceRA Capital Management exited their position in Enanta Pharmaceuticals Inc. (ENTA) in Q1 2025, after holding the stock for 2 quarters.
The position was first reported in Q4 2024 and has been tracked across 2 quarterly 13F filings.
ENTA is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for zelicapavir in 259 days (Dec 31, 2026), making the timing of RA Capital's position particularly relevant.
About Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
Full company profile →Short Interest
8.9%
11.2 days to cover
RA Capital Management ENTA Position History
Frequently Asked Questions
Does RA Capital Management own ENTA?
No. RA Capital Management exited their position in Enanta Pharmaceuticals Inc. (ENTA) in Q1 2025. They previously held the stock for 2 quarters.
How many hedge funds own ENTA?
3 specialist biotech hedge funds currently hold ENTA, including Deep Track Capital, Commodore Capital, Tang Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy ENTA?
RA Capital Management's position in ENTA was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's ENTA position increasing or decreasing?
RA Capital Management completely exited their ENTA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ENTACompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →